Mayne Pharma Group (MAYNF) Stock Price, News & Analysis

Company Overview

Mayne Pharma Group is an Australian specialty pharmaceutical company that develops, manufactures and commercializes branded, generic and specialty medicines. Its portfolio has included prescription products in areas such as women’s health, dermatology and oral and transdermal drug delivery.

The company has also provided pharmaceutical development and contract manufacturing services, supporting the formulation, production and commercialization of medicines for other pharmaceutical companies. Its operations and commercial activities have served markets in Australia, the United States, Canada and other international regions.

Mayne Pharma was established as an independent pharmaceutical business following the separation of pharmaceutical operations from Mayne Nickless. The company was headquartered in Adelaide, South Australia, and historically traded on the Australian Securities Exchange. In 2024, Mayne Pharma was acquired by Cosette Pharmaceuticals, becoming part of that privately held pharmaceutical group.

Key Stats

• Today's Range: $1.87 to $1.97
• 50-Day Range: $1.87 to $2.37
• 52-Week Range: $1.40 to $4.00
• Volume: 8,135 shs
• Average Volume: 3,405 shs
• Market Capitalization: N/A
• P/E Ratio: 51.94
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mayne Pharma Group Stock Analysis - MarketRank™

Mayne Pharma Group scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mayne Pharma Group.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mayne Pharma Group is 51.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mayne Pharma Group is 51.94, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.13.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Mayne Pharma Group has a short interest ratio ("days to cover") of 33.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Mayne Pharma Group has recently decreased by 31.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mayne Pharma Group does not currently pay a dividend.

Dividend Growth

Mayne Pharma Group does not have a long track record of dividend growth.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: N/A

News Sentiment

Mayne Pharma Group has a news sentiment score of -0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Mayne Pharma Group this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mayne Pharma Group insiders have not sold or bought any company stock.

Percentage Held by Institutions

15.80% of the stock of Mayne Pharma Group is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MAYNF
• CIK: N/A
• Web: www.maynepharma.com
• Phone: (188) 209-2666
• Fax: N/A
• Employees: 780
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 51.94
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A